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ABSTRACT. 
Gold nanoparticles modified with anti-mouse IgG have been used to trace 
oligonucleotides carrying a c-myc peptide. Two strategies, a dot-blot format 
as well as inductively coupled plasma mass spectrometry (ICPMS) have 
been used to detect the nanoparticle tracer. For both cases, oligonucleotide-
peptide conjugates were first applied to a nitrocellulose membrane using a 
manifold attached to a suction device. After immobilization of the 
oligonucleotide by UV radiation, the samples were incubated with an anti-c-
myc monoclonal antibody. In the case of the dot-blot format strategy, it 
was followed by incubation with a secondary antibody conjugated to 
horseradish peroxidase and development with luminol as chemiluminescent 
substrate. In the case of ICPMS strategy, it was followed by incubation with 
the secondary antibody (antimouse IgG) conjugated to gold nanoparticles 
and their ICPMS detection after dissolving. The nonspecific adsorptions were 
found to be around zero. The limit of detection for peptide-modified DNA 
was 0,2 pmol. The method may have significant potential as an important 
ICPMS-based nonradioactive DNA detection method for the simultaneous 
determination of various sequences by labeling different kinds of inorganic 
nanoparticles. 
 
INTRODUCTION 
 
The detection of DNA hybridization is of central importance to the 
diagnosis and treatment of genetic diseases, for the detection of infectious 
agents, and for reliable forensic analysis. Recent activity has focused on the 
development of DNA hybridization assays based on various labeling 
techniques. To improve the DNA assay sensitivity, to arrive at better and 
more reliable analysis as well as the simultaneous detection there is a great 
demand for labels with higher specific activity.  
Last, nanoparticles have been using as a novel label for DNA 
hybridization detection. In general, this novel labeling technology is based 
on the unique physical properties of metal nanoparticle materials, including 
large extinction and scattering coefficients, catalytic activity, surface 
electronics, and efficient Brownian motion in solution (1,2). 
Gold nanoparticles that are functionalized with proteins have long 
been used tools in the biosciences (3). Mirkin et al. have shown how 
oligonucleotides can be used to modify the surfaces of such particles.4 
Interesting applications of nanoparticles for the development of 
electrochemical DNA sensors are reported (5). Gold nanoparticles are 
excellent candidates for bioconjugation. They are biocompatible, bind 
readily to a range of biomolecules such as amino acids (6), 
proteins/enzymes (7), and DNA (8), and expose large surface areas for 
immobilization of biomolecules. Gold-based bioassays have been generally 
based on SPR (9) or electrochemical detection (5,7). 
Inductively coupled plasma mass spectrometry (ICPMS) have been 
already used to study the atomization of nanoparticles for developing a 
novel nonradioactive immunoassay by coupling this technique with the 
sandwich-type immunoreaction. For example, the goat anti-rabbit 
immunoglobulin G (IgG) labeled with colloidal gold nanoparticles has served 
as analyte in ICPMS for the indirect measurement of rabbit anti-human IgG. 
A relatively good correlation between the proposed method and enzyme-
linked immunosorbent assay has been reported (10). An ICPMS-linked 
immunoprecipitation assay involving protein A and gold 
nanoparticlemodified antibodies have also been developed in a similar way 
(11). 
 
Chart 1. Sequence of the Oligonucleotide-Peptide Used 
 
 
 
We report an attempt to measure directly the atomic composition of 
gold nanoparticles conjugated to oligonucleotides carrying the c-myc 
peptide via antibody interaction by the use of ICPMS. Oligonucleotide-
peptide conjugates are chimeric molecules made by oligonucleotides 
covalently linked to peptide sequences. They are produced to transfer some 
of the biological or biophysical properties of peptides to synthetic 
oligonucleotides (12,13). The introduction of peptides into oligonucleotide 
sequences has resulted in the introduction of a higher number of multiple 
nonradioactive labels (14). Recently, the introduction of epitope peptide 
sequences into oligonucleotides as a nonradioactive labeling system was 
also described (15). 
 
EXPERIMENTAL SECTION 
 
Apparatus and Procedures. An ICPMS instrument (model PqExCell, 
Thermo Elemental, Windsford, U.K.) was used for the gold quantification. A 
UV-visible spectrophotometer (Kontron Uvikon 943) was used for the 
oligonucleotide quantification. A dot-blot manifold apparatus (Biorad, 162-
0112) attached to a suction device was used for the nonradioactive 
detection of oligonucleotides carrying the c-myc peptide. 
 
Reagents. Oligonucleotide-peptide conjugate, with a c-myc peptide 
with a structure as shown in Chart 1, have been prepared as reported 
previously (16). 
Other reagents included mouse monoclonal antibody antic- myc 
(9E10, hybridoma supernatant), goat anti-mouse-Au colloidal (Sigma, G-
7652; see more details in Supporting Information), goat anti-mouse-HRP 
(Jackson) phosphate buffer saline (PBS: 150 mM NaCl, 20 mM sodium 
phosphate, pH 7.4), Tween 20 (Merck), 0.5 M NaCl (Merck), and bovine 
serum albumin (BSA) (Calbiochem).  
Nitrocellulose membrane, 0.2 µm, and transfer medium (Bio-Rad, Ref 
162-0112) were used for the dot- blot experiment. 
The lyophilized oligonucleotides samples were reconstituted with 1 
mL of Milli-Q water. The oligonucleotide quantification was carried out at 
260 nm by using the UV-visible spectrophotometer, and the concentrations 
of the oligonucleotides were determined. Stock solutions of 830 µg/mL of 
the c-myc-oligonucleotide and a 660 µg/mL of the oligonucleotide without 
peptide were prepared.  
All the reagents used for the digestion and preparation of the samples 
and standard solutions for ICPMS measurements were of spectroscopic 
grade. Milli-Q water was used throughout the reagent preparation. 
 
Experimental Procedure. Assay Protocol of the Oligonucleotide 
Carrying the c-myc Peptide. The assay protocol was conducted following 
the steps of a typical dot-blot assay (Figure 1). Serial halffold dilutions of 
oligonucleotide starting from 8 µg/ dot were applied onto the nitrocellulose 
membrane. The peptide-conjugated oligonucleotide is immobilized by UV 
radiation. UV radiation or baking at 70 ºC are the standard methods to 
immobilize nucleic acids on nitrocellulose or nylon membranes. They are 
especially indicated for long genomic DNA sequences. UV cross-linking is 
preferred for small DNA fragments. Extensive UV cross-linking that may 
interfere with hybridization (particularly in A-T sequences where T-T dimers 
can be produced) is avoided by using short-time UV exposures as we do in 
our experiment (15 s). The membrane was then blocked with PBS 
containing 1% Tween 20 for 1 h. The membrane was washed for three 
times with PBS and then incubated at 4 ºC overnight with the primary 
antibody (9E10 anti-c-myc hybridoma supernatant).  
 
 Figure 1. Schematic presentation of the assay protocol. The nitrocellulose 
membrane (a) was introduced into the dot-blot manifold. The 
oligonucleotide carrying c-myc peptide (b) is immobilized over the 
membrane (c). It reacts overnight with the anti-cmyc (d). The immobilized 
oligonucleotide (e) is then treated: 1. According to the dot-blot assay it 
reacts first with the anti c-myc and goat antimouse HRP-conjugate antibody 
(f1) and then developed (h1) following the ECL (Amersham) protocol and 
exposing to X-ray film. 2. According to the ICPMS-linked assay it reacts for 
1 h with goat anti mouse colloidal Au (f2) and then is dissolved (h2) and 
detected by ICPMS (see details in Supporting Information). Also shown in 
that figure are the following: autoradiography of the oligonucleotide with 
peptide c-myc (column 1), and the oligonucleotide without peptide (column 
2 - blank). Amounts of oligonucleotide-peptide conjugates: 8 (1), 4 (2), 2 
(3), 1 (4), 0.5 (5), 0.25 (6), 0.125 (7), and 0 (8) µg of oligonucleotide/dot. 
 
 
 
 
 
 
 
Table 1. ICPMS Operating Parameter 
Generator power 1350 W 
Generator frequency 27.15 MHz 
Integration time 120 s 
Ar plasma flux 13-15 Lmin-1 
Auxiliary Ar flux 0.90-0.95 Lmin-1 
Nebulizer Ar flux 0.85-0.95 Lmin-1 
Peristaltic pump flux 2 mLmin-1 
Acquisition time 30 s 
Washing time 80 s 
mode Peak jump 
Channels/mass 100 
scans 20 
Time/mass 10000 µs 
 
Detection via Dot-Blot Assay. To carry out the detection via enzymatic 
recognition (see Figure 1, f1-h1), the membrane was incubated with anti c-
myc (9E10 hybridoma supernatant) overnight at 4 ºC. The membrane was 
washed with PBS 1x+ 1% Tween 20 four times for 10 min at room 
temperature and incubated with goat anti-mouse-HRP conjugated antibody 
(Jackson) for 1 h at room temperature. The blot was further developed with 
ECL (Amersham) and exposed to X-ray film. 
 
Detection via ICPMS-Linked Assay. The membrane was incubated with 
anti-c-myc (9E10 hybridoma supernatant) overnight at 4 ºC. It was then 
washed with PBS 1x + 1% Tween 20 four times for 10 min at room 
temperature and finally incubated with goat anti-mouse-colloidal gold 
conjugated antibody (Sigma G-7652) diluted 1:100 in 0.5 M NaCl buffer 
containing 0.1% BSA, 0.05% Tween 20, and 5% fetal bovine serum for 1 h 
at room temperature. 
The membrane was cut carefully into small and identical squares 
according to the deposition areas of DNA. Each square was precisely 
weighed and introduced into a 2-mL glass vial, where it was digested with 
0.5 mL of aqua regia. (Please pay special attention to this hazardous 
procedure!) After the digestion was completed, each sample was diluted to 
10 mL in water and analyzed by ICPMS. The ICPMS operating conditions are 
described in the Table 1. 
To be able to discard unspecific interactions of the different reagents 
used in ICPMS-linked experiments, three blank assays were designed (see 
Figure 2, upper part). The first blank was thought to prove the unspecificity 
of the secondary antibody with the peptide of the oligonucleotide; so a 
direct incubation of the secondary antibody with the oligonucleotide was 
done (without the primary antibody incubation). The second blank was 
thought to prove the unspecificity of the primary antibody with the 
membrane, after being blocked, so a direct incubation of the primary and 
the secondary antibodies onto the membrane was carried out (without any 
oligonucleotide). The third blank was thought to prove the unspecificity of 
the secondary antibody with the membrane, after being blocked, so a direct 
incubation of the secondary antibody onto the membrane was performed 
(without any oligonucleotide nor primary antibody).  
All the blanks were treated as explained above and the cut 
membranes were digested and measured by ICPMS. 
 
 
 
Figure 2. Upper part: schematic of the three blanks (B1, B2, B3) used for 
the ICPMS-linked assays. Lower part: gold signal obtained for the positive 
ICPMS-linked assays with decreasing concentrations of the oligonucleotides: 
8 (a), 4 (b), 2 (c), 1 (d), 0,5 (e), 0,25 (f), 0,125 (g), and 0 (h) µg of 
oligonucleotide/dot. Inset figure: schematic representation of phenomenon 
that explains the inhibitory effect of oligonucleotides. 
 
RESULTS AND DISCUSSION 
Two strategies, the classical dot-blot (17) format as reference 
method and ICPMS, the proposed one, have been used to detect the c-myc 
peptide epitope attached to synthetic oligonucleotides (see Figure 1). For 
both cases, oligonucleotide-peptide conjugates were first applied to a 
nitrocellulose membrane using a manifold attached to a suction device. 
After immobilization of the oligonucleotide by UV radiation, the samples 
were incubated with an anti-c-myc monoclonal antibody. In the case of the 
dot-blot (18) format strategy, it was followed by incubation with a 
secondary antibody conjugated to horseradish peroxidase and development 
with luminol as chemiluminescent substrate. The detection limit was 0.125 
µg (8 pmol) of oligonucleotide/dot. In the case of ICPMS strategy, it was 
followed by incubation with the secondary antibody (anti-mouse IgG) 
conjugated to gold nanoparticles and their ICPMS detection after dissolving.  
The enhanced DNA signals obtained by ICPMS of gold tags are 
combined with the high specificity of oligonucleotide-peptide conjugate 
interaction with anti-c-myc monoclonal antibody followed by 
immunoreaction with the secondary antibody (anti-mouse IgG) conjugated 
to gold nanoparticles. 
Since the colloidal Au nanoparticles with extremely high particle 
density have strong adsorption activity, it is necessary to determine the 
extent of the nonspecific binding (NSB) of the goat anti-mouse-Au colloidal 
in the assay. Au signals from NSB were almost zero by adding the 
secondary antibody and the oligonucleotide but not the primary antibody 
(B1), the primary and the secondary antibody without any oligonucleotide 
(B2), or even the secondary antibody only without any oligonucleotide or 
primary antibody (B3), indicating an excellent NSB level. 
The efficiency of the immobilization of c-myc-oligonucleotide is 
reflected in the obtained results. It depends on the immobilization 
parameters and directly affects the sensitivity as well as the reproducibility 
of the method.  
Taking in the consideration that the detection limit of the ICPMS is at 
~20 ng of Au/g of solution, it can be deduced that 3 ng/dot that corresponds 
to 0.2 pmol (equal with 200 fmol) of DNA can be detected. This detection 
limit is ~40 times lower compared to the dot-blot format. By using a gold 
nanoparticle/ latex microsphere-based colorimetric detection method, Mirkin 
et al. found that for a single-strand DNA the detection limit was 500 pM 
(19). The detection limit can be further lowered by using the 1:1 Au 
nanoparticle-antibody in analogy with a Au nanoparticle- DNA conjugate 
that avoids the creation of an interconnected network of Au-DNA 
immobilization platforms (20). 
For the studied concentration range of the oligonucleotides (Figure 2, 
lower part), an inhibitory effect might have occurred and is rather evident 
at the low-concentration range. This phenomenon could be produced by a 
steric impediment of the antibody recognition (schematic inset). The use of 
other oligonucleotides carrying the c-myc peptide at the extreme part 
should decrease the inhibitory effect observed due to a better exposition 
during the antibody recognition and consequently increase the sensibility as 
well as decrease the detection limit. The use of other metal nanoparticles 
with a higher ICPMS sensitivity will certainly improve the oligonucleotide 
detection limit. 
 
CONCLUSIONS 
This ICPMS-linked DNA detection offers several advantages. The tag is 
directly analyzed giving the possibility for oligonucleotide quantification at 
even very low detection limits. It is reasonable to expect that multiple 
tagged secondary antibodies connected with primary peptide sequence 
antibodies can be used for simultaneous determination in the same sample. 
The immediate acidification of the reacted and separated sample allows for 
long-term storage before analysis and simplifies assay protocols. The 
stability of nanoparticles under UV and visible light makes possible a long-
term monitoring of the environment, for instance, for biological warfare 
agents or natural pathogenic organisms such as cholera and Escherichia 
coli, which represent a critical problem for countries with limited water 
treatment capabilities. 
Although in a very early stage, the proposed ICPMS-linked DNA assay 
may have significant potential as an important nonradioactive DNA 
detection method for the simultaneous determination of various sequences 
by labeling different kinds of inorganic nanoparticles and taking also 
advantage of the recent development of the ICPMS technique. This study 
will also be of interest for the development of novel nylon membrane 
genosensors (21) and DNA chips based on multiple labeling (22) by specific 
immunoreactions with the peptide sequences introduced into the DNA 
probes. The possibility of using the large diversity of available antibodies 
and their many epitope sequences makes oligonucleotide-peptide 
conjugates good candidates for the directed assembly of complex 
nanoparticles (16). The DNA modification via peptide method and 
consecutive antigenin/antibody reaction can be even used for developing 
multiple genosensor platforms based on the same label. Moreover, this 
approach can solve the problem of nonspecific adsorption coming from the 
limited available attachment mechanisms such as biotoin/streptavidin or 
covalent reactions used to label the DNA strands (23). 
The proposed method is a general one with a broad range of 
application possibilities offered by metallic labels easily detected by the 
ICPMS technique. The application of this method in real samples is still in 
process in our laboratories and will be the object of future publications. 
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Supporting Information, Figure S-1 
Au ICP-MS Spectra of Au (m/z = 197). Fast scan along the mass range (20 
sweeps, 300ms, 10 channels per mass, acquisition time 4s). Lines: Dark 
blue: 0,1 ppb; green: 0,3ppb; yellow: 0,5ppb; sky blue: sample (Au coming 
from Au-DNA-membrane digestion) . 
 
 
 
Supporting Information, Figure S-2 
Au calibration line in peak jump mode. Shown are the ICPMS counts vs. 
gold concentration in ppb. Conditions: 100 sweeps, 1 channel per mass, 6 s 
acquisition time. 
 
Data on the Goat anti-Mouse- Au colloidal (Sigma, G-7652) used. 
It is an affinity isolated antibody to mouse IgG (whole molecule) 10 nm 
colloidal gold labeled (monodisperse). According to Sigma information on 
this product the antibody is conjugated to gold by a modification of 
Geoghagan's method (1). The supplied conjugate can be tested for 
immunoreactivity using the dot blot assay of Brada and Roth (2). The 
product is supplied as suspensions in 20% glycerol with 1% BSA, 0.02 M 
Tris buffered saline, pH 8.0 and 0.05% sodium azide. 
(1). W.D. Geoghegan et al., Immunol. Comm., 1978, 7, 1. 
(2). D. Brada and J. Roth, Anal. Biochem., 1984, 142, 79. 
 
